CD274 and neoplasm: This was different from that of the NADIM II and CheckMate 816 trials, where the pCR benefit was greater with increasing PD-L1 expression levels.6,12 However, we acknowledge that our findings were insensitive owing to the small sample size and the fact that more than 50% of patients had an unknown PD-L1 TPS because of inadequate baseline tumor tissues.